PubRank

G J Peters

Author PubWeight™ 226.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000 2.60
2 Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002 2.34
3 Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991 1.77
4 Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996 1.74
5 Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999 1.72
6 MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 1999 1.59
7 Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999 1.50
8 Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999 1.43
9 The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005 1.41
10 Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000 1.40
11 Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999 1.38
12 Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986 1.33
13 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993 1.32
14 Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ 2013 1.27
15 Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000 1.26
16 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004 1.23
17 Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000 1.21
18 Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 1999 1.20
19 Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999 1.19
20 Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 2001 1.14
21 Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994 1.14
22 Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 2003 1.12
23 Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995 1.11
24 The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol 2001 1.11
25 Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994 1.10
26 Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002 1.09
27 Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999 1.09
28 Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol 2012 1.08
29 A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998 1.08
30 DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol 2009 1.07
31 Reproducible gene expression measurement among multiple laboratories obtained in a blinded study using standardized RT (StaRT)-PCR. Mol Diagn 2001 1.06
32 Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus 2004 1.06
33 mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia 2000 1.05
34 Combination chemotherapy studies with gemcitabine. Semin Oncol 1997 1.04
35 Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 1998 1.04
36 Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur J Cancer 2003 1.02
37 End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res 2001 1.02
38 Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 2000 1.02
39 The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 2000 1.01
40 The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol 2012 1.01
41 Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 1999 1.01
42 Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003 0.99
43 Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 1984 0.99
44 [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 2008 0.98
45 Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 1986 0.98
46 Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 2002 0.98
47 Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995 0.98
48 Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999 0.97
49 Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 2000 0.96
50 Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim Biophys Acta 2000 0.96
51 Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 1999 0.96
52 Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol 2008 0.96
53 Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 1988 0.95
54 Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol 1998 0.95
55 Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 2008 0.95
56 Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 2001 0.95
57 Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol 1994 0.95
58 Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 2001 0.95
59 DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 1995 0.95
60 Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 1992 0.94
61 The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem Pharmacol 2007 0.93
62 Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008 0.93
63 Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br J Cancer 2011 0.92
64 Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996 0.92
65 Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann Oncol 2011 0.91
66 Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer 2009 0.91
67 Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 1999 0.91
68 Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 2000 0.91
69 Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 2004 0.91
70 Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin Oncol 1994 0.91
71 Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia. Leuk Res 1992 0.91
72 Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011 0.91
73 Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol 1999 0.90
74 Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2005 0.90
75 The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics. Biochem Pharmacol 1997 0.90
76 Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer 2008 0.90
77 The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006 0.90
78 Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005 0.90
79 Design of new drug molecules to be used in reversing multidrug resistance in cancer cells. Curr Cancer Drug Targets 2009 0.90
80 Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007 0.89
81 Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol 2005 0.89
82 Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 2003 0.89
83 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 2001 0.89
84 Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ 2002 0.89
85 Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004 0.89
86 Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids 2006 0.89
87 DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects. Biochem Pharmacol 1988 0.88
88 Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995 0.88
89 Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. Int J Oncol 2010 0.88
90 Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Curr Med Chem 2009 0.88
91 Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010 0.88
92 Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model. Clin Cancer Res 1996 0.87
93 Detecting medical problems in dentistry: a survey of 4,087 patients in The Netherlands. Eur J Med 1992 0.87
94 Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 2004 0.87
95 New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase. Pharm World Sci 1994 0.87
96 Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 2005 0.87
97 Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer 1992 0.87
98 Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells. Nucleosides Nucleotides Nucleic Acids 2010 0.87
99 Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 1991 0.87
100 Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res 1998 0.86
101 Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem Pharmacol 2001 0.86
102 Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. Acta Oncol 2001 0.86
103 Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil. Oncol Rep 2004 0.86
104 Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Cancer Res 1995 0.86
105 New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase. Pharm World Sci 1994 0.86
106 Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer 1997 0.85
107 Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2007 0.85
108 Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780. Semin Oncol 1995 0.85
109 Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids 2004 0.85
110 UFT: mechanism of drug action. Oncology (Williston Park) 2000 0.85
111 Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun 2003 0.85
112 Postconfluent multilayered cell line cultures for selective screening of gemcitabine. Eur J Cancer 1998 0.85
113 Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 2008 0.85
114 Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 1994 0.85
115 Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol Rep 2007 0.85
116 Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2005 0.85
117 Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation. Oncol Rep 2006 0.84
118 Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids 2011 0.84
119 Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. Biochem Pharmacol 1993 0.84
120 Simultaneous determination of F-beta-alanine and beta-alanine in plasma and urine with dual-column reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001 0.84
121 Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999 0.84
122 Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine. Cancer Chemother Pharmacol 1993 0.84
123 Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol Res 2000 0.84
124 The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells. Int J Biochem Cell Biol 2006 0.84
125 Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 1993 0.84
126 Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000 0.83
127 Stimulation by phytohaemagglutinin of peripheral blood lymphocytes from horse, pig, sheep and man. Vet Immunol Immunopathol 1982 0.83
128 Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 1999 0.83
129 Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci 2008 0.83
130 Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. Oncol Res 1994 0.83
131 Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999 0.83
132 Towards tailored therapy of glioblastoma multiforme. J Chemother 2011 0.83
133 Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 2000 0.83
134 Tissue homogenization using a micro-dismembrator for the measurement of enzyme activities. Clin Chim Acta 1986 0.83
135 Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 2000 0.83
136 Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br J Cancer 2003 0.83
137 Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines. Int J Oncol 2003 0.83
138 Purine and pyrimidine metabolism in peripheral blood lymphocytes. Int J Biochem 1983 0.83
139 A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Eur J Cancer 2009 0.83
140 Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents. J Chemother 2009 0.83
141 Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem Pharmacol 1997 0.83
142 Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Gen Pharmacol 1996 0.83
143 Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 1999 0.83
144 Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil. Anticancer Res 1993 0.83
145 A sensitive, nonradiometric assay for dihydroorotic acid dehydrogenase using anion-exchange high-performance liquid chromatography. Anal Biochem 1987 0.82
146 Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas. Cancer Chemother Pharmacol 1996 0.82
147 A sensitive non-radioactive assay for pyrimidine nucleoside phosphorylase using reversed-phase high performance liquid chromatography. Clin Chim Acta 1988 0.82
148 Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1992 0.82
149 The role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior. Nucleosides Nucleotides Nucleic Acids 2008 0.82
150 Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des 2013 0.82
151 Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 2000 0.82
152 Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J Histochem Cytochem 2000 0.82
153 Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 2004 0.82
154 Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates. Br J Cancer 1992 0.82
155 The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis 2013 0.82
156 The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer 2006 0.81
157 Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Int J Oncol 2001 0.81
158 Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC). Adv Exp Med Biol 1998 0.81
159 A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors. Nucleosides Nucleotides Nucleic Acids 2004 0.81
160 No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil. Adv Exp Med Biol 1998 0.81
161 Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines. Adv Exp Med Biol 1993 0.81
162 Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. Exp Hematol 2001 0.81
163 Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines. Adv Exp Med Biol 1998 0.81
164 Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs. Eur J Cancer 1998 0.81
165 Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Adv Exp Med Biol 1998 0.80
166 Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 1998 0.80
167 Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004 0.80
168 Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol 2004 0.80
169 Changes in glycosylation of L1210 cells after exposure to various antimetabolites. Eur J Cancer 1993 0.80
170 Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. Nucleosides Nucleotides Nucleic Acids 2004 0.80
171 Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. Br J Haematol 2005 0.80
172 Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. Ann Oncol 1993 0.80
173 In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis. Br J Cancer 1993 0.80
174 Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate. Nucleosides Nucleotides Nucleic Acids 2004 0.80
175 Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures. Biochem Pharmacol 1994 0.80
176 Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. Eur J Cancer Clin Oncol 1984 0.80
177 In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of five organotin compounds. In Vivo 1995 0.79
178 A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. Eur J Cancer 2001 0.79
179 Re: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999 0.79
180 Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 1999 0.79
181 Increased migration by stimulation of thymidine phosphorylase in endothelial cells of different origin. Nucleosides Nucleotides Nucleic Acids 2010 0.79
182 Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. Braz J Med Biol Res 2001 0.79
183 Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine). Adv Exp Med Biol 1991 0.79
184 MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside. Curr Med Chem 2014 0.79
185 No evidence of gemcitabine accumulation during weekly administration. Eur J Clin Pharmacol 2005 0.79
186 Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells. Biochem Pharmacol 2010 0.79
187 Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase. Semin Oncol 1992 0.79
188 Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Leuk Res 1996 0.79
189 Effect of folate diastereoisomers on the binding of 5-fluoro-2'-deoxyuridine-5'-monophosphate to thymidylate synthase. Biochem Pharmacol 1993 0.79
190 In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 1988 0.78
191 Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Eur J Cancer 1995 0.78
192 Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines. Effects of drugs. FEBS Lett 1984 0.78
193 New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol 2010 0.78
194 Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2006 0.78
195 Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia. Nucleosides Nucleotides Nucleic Acids 2014 0.78
196 18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: a study for a correlation with oncological results. Nucl Med Biol 1996 0.78
197 Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor. J Clin Oncol 2001 0.78
198 Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. Eur J Cancer 1993 0.78
199 Troxacitabine prodrugs for pancreatic cancer. Nucleosides Nucleotides Nucleic Acids 2007 0.78
200 Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines. Adv Exp Med Biol 1998 0.78
201 Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies. Eur J Pharm Sci 2011 0.78
202 Expression of 5'-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage. Blood 1991 0.78
203 Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 2010 0.78
204 CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Oncol Rep 2008 0.78
205 Mechanisms of synergism between gemcitabine and cisplatin. Adv Exp Med Biol 1998 0.78
206 Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2000 0.78
207 The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells. Life Sci 2000 0.78
208 In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides. Eur J Cancer 1991 0.78
209 Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts. Cancer Lett 1990 0.78
210 Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines. J Chemother 2009 0.78
211 Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line. Nucleosides Nucleotides Nucleic Acids 2004 0.78
212 Determination of the antimetabolite Gemcitabine (2',2'-difluoro-2'-deoxycytidine) and of 2',2'-difluoro-2'-deoxyuridine by 19F nuclear magnetic resonance spectroscopy. Anal Biochem 1993 0.78
213 Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids 2004 0.78
214 Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity. J Chemother 2005 0.78
215 Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines. Oncol Res 1999 0.78
216 Toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of di- and triorganotin compounds. Met Based Drugs 1998 0.78
217 In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine. Nucleic Acids Symp Ser (Oxf) 2008 0.77
218 Synthesis and in vitro cytotoxicity of long chain 2-amino alcohols and 1,2-diamines. Anticancer Res 2001 0.77
219 Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer 1992 0.77
220 Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. Oncol Res 1995 0.77
221 Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells. Adv Enzyme Regul 1997 0.77
222 Addition of leucovorin in modulation of 5-fluorouracil with methotrexate: potentiating or reversing effect? Int J Cancer 1995 0.77
223 Modulation of fluorouracil toxicity with uridine. Semin Oncol 1992 0.77
224 Online fluorescent method to assess BCRP/ABCG2 activity in suspension cells. Nucleosides Nucleotides Nucleic Acids 2004 0.77
225 The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites. Int J Biochem 1985 0.77
226 The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat. Eur J Cancer 1995 0.77
227 Adenosine and deoxyadenosine metabolism in mammalian lymphocytes. Int J Biochem 1981 0.77
228 Combinations of 5-fluorouracil with UCN-01 or staurosporine. Nucleosides Nucleotides Nucleic Acids 2004 0.77
229 Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. Cancer Chemother Pharmacol 2004 0.77
230 Intermittent continuous infusion of 5-fluorouracil and low dose oral leucovorin in patients with gastrointestinal cancer: relationship between plasma concentrations and clinical parameters. Eur J Cancer 1995 0.77
231 Enhanced activity of deoxycytidine kinase after pulsed low dose rate and single dose gamma irradiation. Nucleosides Nucleotides Nucleic Acids 2006 0.77
232 Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS. Nucleosides Nucleotides Nucleic Acids 2011 0.77
233 Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur Urol 2003 0.77
234 5-fluorouracil/leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and man. J Cancer Res Clin Oncol 1997 0.77
235 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil. J Cancer Res Clin Oncol 1999 0.77
236 Concentration of nucleotides and deoxynucleotides in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. Effects of adenosine and deoxyadenosine. Biochim Biophys Acta 1983 0.77
237 Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells. Nucleosides Nucleotides Nucleic Acids 2006 0.77
238 Synthesis, in vitro cytotoxicity and in vivo anti-inflammatory activity of long chain 3-amino-1,2-diols. Bioorg Med Chem Lett 1999 0.77
239 Upregulation of platelet derived endothelial cell growth factor/thymidine phosphorylase by interferon alpha. Nucleosides Nucleotides Nucleic Acids 2004 0.76
240 Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood 1999 0.76
241 Similar changes were induced by Cladribine and by gemcitabine, in the deoxypyrimidine salvage, during short-term treatments. Adv Exp Med Biol 1998 0.76
242 Cross-resistance to thymidylate synthase inhibitors in P-glycoprotein and non-P-glycoprotein cell lines. Adv Exp Med Biol 1994 0.76
243 Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. Nucleosides Nucleotides Nucleic Acids 2008 0.76
244 Effect of suramin on adenylate cyclase and protein kinase C. Anticancer Drug Des 1994 0.76
245 Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate. Biochem Pharmacol 1994 0.76
246 Analysis of deoxycytidine accumulation in gemcitabine treated patients. Nucleosides Nucleotides Nucleic Acids 2006 0.76
247 Limited intra-individual variability in hypoxanthine-Guanine phosphoribosyl transferase, thiopurine S-methyl transferase, and xanthine oxidase activity in inflammatory bowel disease patients during 6-thioguanine therapy. Nucleosides Nucleotides Nucleic Acids 2010 0.76
248 Comparison of 5-fluoro-2'-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase. Adv Exp Med Biol 1994 0.76
249 Adenosine deaminase and purine nucleoside phosphorylase in childhood lymphoblastic leukemia: relation with differentiation stage, in vitro drug resistance and clinical prognosis. Leukemia 1992 0.76
250 Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. Leukemia 2002 0.76
251 Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin. Nucleosides Nucleotides Nucleic Acids 2008 0.76
252 Deoxyribose protects against rapamycin-induced cytotoxicity in colorectal cancer cells in vitro. Nucleosides Nucleotides Nucleic Acids 2011 0.76
253 Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity. Nucleosides Nucleotides Nucleic Acids 2004 0.76
254 Purine and pyrimidine metabolism: still a black box? Pharm World Sci 1994 0.76
255 Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 2001 0.75
256 The effect of schedule, protein binding and growth factors on the activity of suramin. Int J Cancer 1992 0.75
257 The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB. Br J Cancer 2011 0.75
258 Development of new molecular agents targeting key signalling pathways activated by growth factors in human cancer. Curr Pharm Des 2013 0.75
259 Synthesis and in vitro cytotoxicity of novel long chain busulphan analogues. Bioorg Med Chem Lett 2001 0.75
260 Metabolism of phosphoribosylpyrophosphate in peripheral and phytohemagglutin-stimulated mammalian lymphocytes. Int J Biochem 1981 0.75
261 Effects of adenosine and deoxyadenosine on PHA-stimulation of lymphocytes of man, horse and pig. Int J Biochem 1982 0.75
262 L-Dopa stimulates expression of the antioxidant enzyme NAD(P)H:quinone oxidoreductase (NQO) in cultured astroglial cells. Free Radic Biol Med 2000 0.75
263 Isolated liver perfusion versus hepatic artery infusion with 5-fluorouracil in a rat model; effects on thymidylate synthase. Adv Exp Med Biol 1991 0.75
264 Separation of 5-fluorouracil and uracil by ion-pair reversed-phase high-performance liquid chromatography on a column with porous polymeric packing. J Chromatogr 1984 0.75
265 Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose. Cancer Chemother Pharmacol 1990 0.75
266 Pyrimidine metabolism in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. Int J Biochem 1983 0.75
267 Fluoropyrimidine metabolism in human head and neck cancer xenografts and murine colon tumors. Adv Exp Med Biol 1989 0.75
268 Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids 2008 0.75
269 The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531. J Surg Oncol 1995 0.75
270 Discrepancies in ribonucleotide concentrations in human lymphocytes isolated from heparinized and defibrinized blood. Clin Chim Acta 1985 0.75
271 Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine). Adv Exp Med Biol 1998 0.75
272 Metabolism of guanosine and deoxyguanosine in mammalian lymphocytes and their influence on mitogenic stimulation. Adv Exp Med Biol 1984 0.75
273 Metabolism of purine nucleosides in human and ovine lymphocytes and rat thymocytes and their influence on mitogenic stimulation. Biochim Biophys Acta 1983 0.75
274 Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma. Invest New Drugs 1989 0.75
275 Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. J Natl Cancer Inst 1989 0.75
276 Pyrimidine metabolism in lymphocytes and erythrocytes of man, horse and cattle. Int J Biochem 1979 0.75
277 Preclinical and clinical biochemical modulation of 5-fluorouracil by leucovorin and uridine. Sci Rep Res Inst Tohoku Univ Med 1988 0.75
278 Modulation of cytotoxicity and metabolism of 5-fluorouracil in two intestine cell lines. Adv Exp Med Biol 1986 0.75
279 Biological activity of 1-deazapurine nucleosides: role of deoxycytidine kinase? Nucleosides Nucleotides 1999 0.75
280 Metabolism of purine nucleosides and phosphoribosylpyrophosphate in thymocytes and splenocytes of various mammalian species. Comp Biochem Physiol B 1982 0.75
281 Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. Anticancer Drugs 1999 0.75
282 The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. Eur J Cancer 1994 0.75
283 Thymidylate synthase inhibition induces p53 dependent and independent cell death. Adv Exp Med Biol 2000 0.75
284 Modulation of 5-fluorouracil in mice using uridine diphosphoglucose. Clin Cancer Res 1997 0.75
285 Toxicity and antitumor effect of 5-fluorouracil and its rescue by uridine. Adv Exp Med Biol 1986 0.75
286 [Treatment results in 951 newborn infants with IRDS (idiopathic respiratory distress syndrome), especially in relation to artificial respiration from 1967 through 1981]. Tijdschr Kindergeneeskd 1984 0.75
287 Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26. Eur J Cancer 1995 0.75
288 In vitro sequence-dependent synergistic effect of suramin and camptothecin. Eur J Cancer 1994 0.75
289 Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR; in relation to enzyme activity. Nucleosides Nucleotides Nucleic Acids 2004 0.75
290 Variable pharmacodynamics of antifolates in squamous cell carcinoma of the head and neck. Adv Exp Med Biol 1993 0.75
291 Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system. Cancer Chemother Pharmacol 1991 0.75
292 Chemosensitizing acridones: in vitro calmodulin dependent cAMP phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies. J Mol Graph Model 2013 0.75
293 Age-dependency of adenosine deaminase and purine nucleoside phosphorylase activities in rat spleen and thymus. Biol Neonate 1982 0.75
294 Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv Exp Med Biol 1994 0.75
295 Novel cell death mechanisms of trifluorothymidine. Nucleic Acids Symp Ser (Oxf) 2008 0.75
296 [20-year follow-up study of 25-31-week-old premature infants]. Ned Tijdschr Geneeskd 1984 0.75
297 Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples. Nucleosides Nucleotides Nucleic Acids 2008 0.75
298 Concentration of nucleotides in peripheral blood lymphocytes of various mammalian species. Adv Exp Med Biol 1984 0.75
299 Chemotherapeutic strategies for treatment of colorectal cancer: present and future developments. Clin Colorectal Cancer 2001 0.75
300 Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectrometry. J Chromatogr 1985 0.75
301 Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR. Nucleosides Nucleotides Nucleic Acids 2004 0.75
302 Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol 1989 0.75
303 Purine metabolism in splenocytes and thymocytes of various mammalian species. Adv Exp Med Biol 1984 0.75
304 In vitro chemosensitivity testing of multilayered microcultures. Anticancer Res 1992 0.75
305 Pyrimidine metabolism in rat brain cortex and liver. Adv Exp Med Biol 1984 0.75
306 Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides Nucleotides Nucleic Acids 2004 0.75
307 Incorporation of 5-fluorouracil into nucleotide sugars and the effect on glycoconjugates in rat hepatoma cells and hepatocytes. Adv Exp Med Biol 1989 0.75
308 The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracil. Adv Exp Med Biol 1998 0.75
309 Enterolith with pseudogallstone ileus. JAMA 1971 0.75
310 Antimetabolite-induced increases in the invasive capacity of murine leukaemia L1210 cells. Clin Exp Metastasis 1994 0.75
311 The interval between methotrexate and leucovorin determines the efficacy of 5-fluorouracil modulation in vitro and in vivo. Adv Exp Med Biol 1993 0.75
312 Concentration, synthesis and utilization of phosphoribosylpyrophosphate in lymphocytes of five mammalian species. Int J Biochem 1979 0.75
313 "The only thing I know is that I know nothing": 5-fluorouracil in human milk. Ann Oncol 2012 0.75
314 Purine nucleotide interconversion enzymes in childhood leukemia: relation with cell cycle and clinical outcome. Adv Exp Med Biol 1994 0.75
315 The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium. Cancer Lett 1989 0.75